1
Sullivan John K, Mcgivern Joseph G, Miranda Leslie P, Nguyen Hung Q, Walker Kenneth W, Hu Shaw Fen Sylvia, Gegg Jr Colin V, Mcdonough Stefan I: Toxin peptides with extended blood halflife. Amgen, STEINBERG Nisan A, November 2, 2006: WO/2006/116156 (22 worldwide citation)

Disclosed is a composition of matter of the formula (I) (X1)a-(F1)d-(X2)b-(F2)e-(X3)c and multimers thereof, in which F1 and F2 are half-life extending moieties, and d and e are each independently 0 or 1, provided that at least one of d and e is 1; X1, X2, and X3 are each independently -(L)f-P-(L)g- ...


2
Sullivan John K, Mcgivern Joseph G, Miranda Leslie P, Nguyen Hung Q, Walker Kenneth W, Hu Shaw Fen Sylvia, Gegg Colin V Jr, Arora, Khare Taruna, Adler Beverly S, Martin Francis H: Toxin peptide therapeutic agents. Amgen, Sullivan John K, Mcgivern Joseph G, Miranda Leslie P, Nguyen Hung Q, Walker Kenneth W, Hu Shaw Fen Sylvia, Gegg Colin V Jr, Arora, Khare Taruna, Adler Beverly S, Martin Francis H, STEINBERG Nisan A, July 24, 2008: WO/2008/088422 (19 worldwide citation)

Disclosed is a composition of matter comprising an OSK1 peptide analog, and in some embodiments, a pharmaceutically acceptable salt thereof. A pharmaceutical composition comprises the composition and a pharmaceutically acceptable carrier. Also disclosed are DNAs encoding the inventive composition of ...


3
SULLIVAN JOHN K: SELECTIVE AND POTENT PEPTIDE INHIBITORS OF KV1.3. AMGEN, Steinberg Nisan A, September 23, 2010: WO/2010/108154 (12 worldwide citation)

Disclosed are compositions of matter having an amino acid sequence of SEQ ID NO:4, or a pharmaceutically acceptable salt thereof, including embodiments comprising a toxin peptide analog related to ShK, HmK, and AETX-K and pharmaceutical compositions or medicaments containing them along with a pharma ...


4
Fox Gary M, Sullivan John K, Fang Mei: B7-like molecules and uses thereof. Amgen, Fox Gary M, Sullivan John K, Fang Mei, ZUHN Donald L, January 10, 2002: WO/2002/002624 (3 worldwide citation)

The present invention provides B7-Like(B7-L) polypeptides and nucleic acid molecules encoding the same. The invention also provides selective binding agents, vectors, host cells, and methods for producing B7-L polypeptides. The invention further provides pharmaceutical compositions and methods for t ...


5
DESHPANDE RAJENDRA V, HITZ ANNA, BOYLE WILLIAM J, SULLIVAN JOHN K: Antagonistic selective binding agents of osteoprotegerin binding protein, Antagonistische selektive Bindungsagenzien des Osteoprotegerin-Bindungsproteins, Agents antagonistes de liaison sélective de protéine de liaison dostéoprotégérine. AMGEN, June 8, 2011: EP2330197-A2 (1 worldwide citation)

Selective binding agents of osteoprotegerin binding protein (OPGbp) are provided by the invention. More particularly, the invention provides for antibodies and antigen binding domains which selectively bind to OPGbp and may be used to prevent or treat conditions relating to loss of bone mass. Nuclei ...


6
Fox Gary Michael, Sullivan John K, Holst Paige, Yoshinaga Steven Kiyoshi: B7-like molecules and uses thereof. Amgen, Fox Gary Michael, Sullivan John K, Holst Paige, Yoshinaga Steven Kiyoshi, ZUHN Donald L, March 28, 2002: WO/2002/024891 (1 worldwide citation)

The present invention provides B7-Like(B7-L) polypeptides and nucleic acid molecules encoding the same. The invention also provides selective binding agents, vectors, host cells, and methods for producing B7-L polypeptides. The invention further provides pharmaceutical compositions and methods for t ...


7
DESHPANDE RAJENDRA V , HITZ ANNA , BOYLE WILLIAM J , SULLIVAN JOHN K : [de] ANTAGONISTISCHE SELEKTIVE BINDEMITTEL EINES OSTEOPROTEGERIN-BINDENDEN PROTEINS, [en] ANTAGONISTIC SELECTIVE BINDING AGENTS OF OSTEOPROTEGERIN BINDING PROTEIN, [fr] AGENTS ANTAGONISTES DE LIAISON SÉLECTIVE DE PROTÉINE DE LIAISON DOSTÉOPROTÉGÉRINE. AMGEN  , June 28, 2017: EP3184545-A1

[en] Selective binding agents of osteoprotegerin binding protein (OPGbp) are provided by the invention. More particularly, the invention provides for antibodies and antigen binding domains which selectively bind to OPGbp and may be used to prevent or treat conditions relating to loss of bone mass. N ...


8
DESHPANDE RAJENDRA V, HITZ ANNA, BOYLE WILLIAM J, SULLIVAN JOHN K: [fr] Agents antagonistes de liaison sélective de protéine de liaison dostéoprotégérine, [de] Antagonistische selektive Bindemittel eines Osteoprotegerin-bindenden Proteins, [en] Antagonistic selective binding agents of osteoprotegerin binding protein. AMGEN, September 30, 2009: EP2105449-A2

[en] Selective binding agents of osteoprotegerin binding protein (OPGbp) are provided by the invention. More particularly, the invention provides for antibodies and antigen binding domains which selectively bind to OPGbp and may be used to prevent or treat conditions relating to loss of bone mass. N ...


9
DESHPANDE RAJENDRA V, HITZ ANNA, BOYLE WILLIAM J, SULLIVAN JOHN K: [fr] Anticorps monoclonal contre la protéine de liaison dostéoprotégérine, [de] Monoklonaler Antikörper gegen das Osteoprotegerin-bindenden Protein, [en] Monoclonal antibody to osteoprotegerin binding protein. AMGEN, April 6, 2011: EP2305715-A2

[en] Selective binding agents of osteoprotegerin binding protein (OPGbp) are provided by the invention. More particularly, the invention provides for antibodies and antigen binding domains which selectively bind to OPGbp and may be used to prevent or treat conditions relating to loss of bone mass. N ...


10
BOYLE WILLIAM J, MEDLOCK EUGENE, SULLIVAN JOHN K, ELLIOTT ROBIN L, MARTIN FRANCIS H, HUANG HAICHUN: Human anti-OPGL neutralizing antibodies as selective OPGL pathway inhibitors, Humane neutralizierende anti-OPGL Antikörper als selektive OPGL Pathway Inhibitoren, Anticorps humain anti-OPGL neutralizant comme inhibiteurs selectifs de la voie de signalisaition par lOPGL. AMGEN, MEDAREX, April 27, 2011: EP2314316-A1

Monoclonal antibodies and hybridomas producing them that interact with osteoprotegerin ligand (OPGL) are provided. Methods of treating osteopenic disorders by administering a pharmaceutically effective amount of antibodies to OPGL are also provided. Methods of detecting the amount of OPGL in a sampl ...